EP1175215A2 - L'osanetant dans le traitement des troubles de l'humeur - Google Patents
L'osanetant dans le traitement des troubles de l'humeurInfo
- Publication number
- EP1175215A2 EP1175215A2 EP00918941A EP00918941A EP1175215A2 EP 1175215 A2 EP1175215 A2 EP 1175215A2 EP 00918941 A EP00918941 A EP 00918941A EP 00918941 A EP00918941 A EP 00918941A EP 1175215 A2 EP1175215 A2 EP 1175215A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- osanetant
- treatment
- disorders
- mood disorders
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the subject of the present invention is a new use of the osanetant.
- the osanetant is the International Nonproprietary Name (INN) of (R) - (+) - N - [(3- (1-benzoyl-3- (3,4-dichlorophenyl) piperidin-3-yl) propyl) -4 - phenylpiperidin-4-yl] -N-methyl acetamide of formula:
- ososetant and its pharmaceutically acceptable salts are useful in the treatment of mood disorders, in particular in the treatment of depression.
- depression is meant in particular major depressive disorders minor depressive disorders, dysthymic disorders, depressive disorders associated with anxiety as well as depressive disorders associated with bipolar disorders.
- ososetant The effect of ososetant on major depressive disorders is studied in patients aged 18 to 65 years. Patients receive osmetanant (200 mg / day) for a period of approximately 6 weeks. The improvement in depressive syndromes is measured by a significant decrease in scores on the Hamilton scale (J. Neurol. Neurosurg. Psychiat., 1960, 23, 56-62) as well as by the collection of impressions from the clinician and overall patient impressions.
- the subject of the present invention is the use of the osanetant and its pharmaceutically acceptable salts for the preparation of drugs useful in the treatment of mood disorders, particularly in the treatment of depression.
- Ososetant and its pharmaceutically acceptable salts are prepared according to European patent application EP 673 928, likewise the pharmaceutical compositions can be prepared according to the description of this same patent application.
- compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration
- the active ingredient alone or in combination with another active ingredient can be administered in unit form of administration, in admixture with conventional pharmaceutical carriers, to animals and humans.
- Suitable unit administration forms include oral forms such as tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, aerosols, implants, forms subcutaneous, transdermal, intramuscular, intravenous, intranasal and rectal administration forms.
- the daily dosage of the compound according to the invention is from 0.05 to 5 mg / kg, advantageously from 1 to 2.5 mg / kg, preferably from 2 to 2.5 mg / kg, to be administered in one or more times.
- the compounds are generally formulated in dosage unit containing from 2.5 to 500 mg, advantageously from 50 to 250 mg, preferably from 100 to 250 mg, of active principle per dosage unit, to be administered once, twice or more times , as required.
- these dosages are examples of average situations, there may be special cases where higher or lower dosages are appropriate, such dosages also belong to the invention.
- the appropriate dosage for each patient is determined by the doctor according to the mode of administration, the age, the weight and the response of said patient.
- oral forms of administration are preferred.
- the compounds according to the invention can be administered in combination with another active principle, in particular another antidepressant such as a lithium salt, a tricyclic antidepressant, a monoamine oxidase inhibitor or a serotonin reuptake reuptake inhibitor, by example.
- another antidepressant such as a lithium salt, a tricyclic antidepressant, a monoamine oxidase inhibitor or a serotonin reuptake reuptake inhibitor, by example.
- the invention also relates to a method of treatment of mood disorders, more particularly, to a method of treatment of depression, by administration to the patient of an appropriate dose of osanetant or of a pharmaceutically salt thereof. acceptable.
- EXAMPLE 1 Capsule with 250 mg of osanetant. osanetant 250 mg lactose monohydrate (200 mesh) 40.80 mg corn starch 40.80 mg povidone K-30 8.40 mg purified water * 90.00 mg magnesium stearate 3.40 mg for an opaque white capsule of size 0 , filled to 343.4 mg
- EXAMPLE 2 Capsule with 100 mg of osanetant. osanetant 100 mg lactose monohydrate (200 mesh) 115.80 mg corn starch 115.80 mg povidone K-30 8.40 mg purified water * 90.00 mg magnesium stearate 3.40 mg for an opaque white capsule of size 0 , filled to 343.4 mg
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9904699 | 1999-04-13 | ||
FR9904699A FR2792199B3 (fr) | 1999-04-13 | 1999-04-13 | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
PCT/FR2000/000924 WO2000061125A2 (fr) | 1999-04-13 | 2000-04-11 | L'osanetant dans le traitement des troubles de l'humeur |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1175215A2 true EP1175215A2 (fr) | 2002-01-30 |
Family
ID=9544412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00918941A Withdrawn EP1175215A2 (fr) | 1999-04-13 | 2000-04-11 | L'osanetant dans le traitement des troubles de l'humeur |
Country Status (25)
Country | Link |
---|---|
US (1) | US6420388B1 (fr) |
EP (1) | EP1175215A2 (fr) |
JP (1) | JP2002541190A (fr) |
KR (1) | KR20010105418A (fr) |
CN (1) | CN1354662A (fr) |
AR (1) | AR023452A1 (fr) |
AU (1) | AU3971600A (fr) |
BG (1) | BG105984A (fr) |
BR (1) | BR0009704A (fr) |
CA (1) | CA2369638A1 (fr) |
CZ (1) | CZ20013645A3 (fr) |
EE (1) | EE200100527A (fr) |
FR (1) | FR2792199B3 (fr) |
HR (1) | HRP20010741A2 (fr) |
HU (1) | HUP0200655A3 (fr) |
ID (1) | ID30458A (fr) |
IS (1) | IS6098A (fr) |
MX (1) | MXPA01010340A (fr) |
NO (1) | NO20014953L (fr) |
PE (1) | PE20010032A1 (fr) |
PL (1) | PL351554A1 (fr) |
SK (1) | SK14552001A3 (fr) |
TR (1) | TR200102930T2 (fr) |
WO (1) | WO2000061125A2 (fr) |
ZA (1) | ZA200108289B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE367811T1 (de) * | 2000-06-12 | 2007-08-15 | Univ Rochester | Methode zur behandlung von hitzewallungen, durch verwendung eines tachikinin-rezeptor antagonisten |
BRPI0417959A (pt) * | 2003-12-22 | 2007-03-27 | Glaxo Group Ltd | anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável |
EP1729751A1 (fr) * | 2004-03-25 | 2006-12-13 | Smithkline Beecham Corporation | Utilisation d'un antagoniste du nk3 pour le traitement de troubles bipolaires |
EP1867717A4 (fr) | 2005-03-15 | 2008-08-20 | Sumitomo Chemical Co | Procédé destiné à améliorer les symptômes provenant de troubles de l'humeur |
JP2006320201A (ja) * | 2005-05-17 | 2006-11-30 | Sumitomo Chemical Co Ltd | 気分障害又は関連障害による疾患症状を改善させる方法 |
GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
US10314835B2 (en) * | 2014-06-25 | 2019-06-11 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2719311B1 (fr) | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR2738819B1 (fr) | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
AU4176997A (en) * | 1996-09-16 | 1998-04-02 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
-
1999
- 1999-04-13 FR FR9904699A patent/FR2792199B3/fr not_active Expired - Fee Related
-
2000
- 2000-04-11 SK SK1455-2001A patent/SK14552001A3/sk unknown
- 2000-04-11 MX MXPA01010340A patent/MXPA01010340A/es not_active Application Discontinuation
- 2000-04-11 ID IDW00200102144A patent/ID30458A/id unknown
- 2000-04-11 CZ CZ20013645A patent/CZ20013645A3/cs unknown
- 2000-04-11 US US09/958,266 patent/US6420388B1/en not_active Expired - Fee Related
- 2000-04-11 PL PL00351554A patent/PL351554A1/xx not_active Application Discontinuation
- 2000-04-11 JP JP2000610458A patent/JP2002541190A/ja not_active Withdrawn
- 2000-04-11 CA CA002369638A patent/CA2369638A1/fr not_active Abandoned
- 2000-04-11 TR TR2001/02930T patent/TR200102930T2/xx unknown
- 2000-04-11 WO PCT/FR2000/000924 patent/WO2000061125A2/fr not_active Application Discontinuation
- 2000-04-11 CN CN00806091A patent/CN1354662A/zh active Pending
- 2000-04-11 EE EEP200100527A patent/EE200100527A/xx unknown
- 2000-04-11 EP EP00918941A patent/EP1175215A2/fr not_active Withdrawn
- 2000-04-11 BR BR0009704-7A patent/BR0009704A/pt not_active Application Discontinuation
- 2000-04-11 HU HU0200655A patent/HUP0200655A3/hu unknown
- 2000-04-11 AU AU39716/00A patent/AU3971600A/en not_active Abandoned
- 2000-04-11 KR KR1020017012990A patent/KR20010105418A/ko not_active Application Discontinuation
- 2000-04-12 AR ARP000101670A patent/AR023452A1/es unknown
- 2000-04-13 PE PE2000000343A patent/PE20010032A1/es not_active Application Discontinuation
-
2001
- 2001-09-28 IS IS6098A patent/IS6098A/is unknown
- 2001-10-05 BG BG105984A patent/BG105984A/bg unknown
- 2001-10-09 ZA ZA200108289A patent/ZA200108289B/xx unknown
- 2001-10-11 NO NO20014953A patent/NO20014953L/no not_active Application Discontinuation
- 2001-10-12 HR HR20010741A patent/HRP20010741A2/hr not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0061125A2 * |
Also Published As
Publication number | Publication date |
---|---|
BR0009704A (pt) | 2002-01-08 |
ZA200108289B (en) | 2002-12-24 |
SK14552001A3 (sk) | 2002-02-05 |
US6420388B1 (en) | 2002-07-16 |
TR200102930T2 (tr) | 2002-04-22 |
PE20010032A1 (es) | 2001-04-11 |
PL351554A1 (en) | 2003-05-05 |
NO20014953D0 (no) | 2001-10-11 |
AR023452A1 (es) | 2002-09-04 |
HUP0200655A2 (hu) | 2002-07-29 |
BG105984A (bg) | 2002-04-30 |
CN1354662A (zh) | 2002-06-19 |
HUP0200655A3 (en) | 2002-11-28 |
KR20010105418A (ko) | 2001-11-28 |
HRP20010741A2 (en) | 2002-10-31 |
CA2369638A1 (fr) | 2000-10-19 |
EE200100527A (et) | 2002-12-16 |
WO2000061125A2 (fr) | 2000-10-19 |
WO2000061125A3 (fr) | 2001-04-19 |
MXPA01010340A (es) | 2002-05-06 |
AU3971600A (en) | 2000-11-14 |
ID30458A (id) | 2001-12-06 |
CZ20013645A3 (cs) | 2002-01-16 |
NO20014953L (no) | 2001-12-11 |
IS6098A (is) | 2001-09-28 |
FR2792199B3 (fr) | 2001-05-18 |
FR2792199A1 (fr) | 2000-10-20 |
JP2002541190A (ja) | 2002-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5075338A (en) | Method of treatment of learning deficiency | |
EP1221952B1 (fr) | UTILISATION D'UN ANTAGONISTE DES RECEPTEURS AUX CANNABINOiDES CENTRAUX POUR LA PREPARATION DE MEDICAMENTS | |
CH672068A5 (fr) | ||
EP0369887B1 (fr) | Utilisation de trifluorométhylphényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles anxio-dépressifs | |
US5220068A (en) | Psychostimulant agent | |
FR2837706A1 (fr) | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles | |
WO2000064423A2 (fr) | Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression | |
WO2000061125A2 (fr) | L'osanetant dans le traitement des troubles de l'humeur | |
EP0429360B1 (fr) | Inhibition du syndrome d'abstinence | |
FR2501506A1 (fr) | Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine | |
EP0412901B1 (fr) | Utilisation de trifluorométhyl-phényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles de la motricité intestinale | |
CH679553A5 (fr) | ||
KR100906893B1 (ko) | 피페리딘-2,6-디온 바이설페이트 염 및 스트레스 관련 정동 장애의 치료를 위한 이의 용도 | |
CH678149A5 (fr) | ||
KR20010110798A (ko) | 신경퇴화의 치료방법 | |
WO2000066117A1 (fr) | Utilisation du (2s)-1- [(2r,3s)-5- chloro-3- (2-chlorophenyl)-1- (3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h-indole-2-carbonyl] pyrrolidine- 2-carboxamide pour la preparation de medicaments utiles dans le traitement du phenomene de raynaud | |
US5270341A (en) | Method of treatment or prophylaxis of depression and stress | |
FR2915100A1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson | |
FR2639227A1 (fr) | Utilisation de derives du chromane pour le traitement des etats depressifs | |
CA2658614A1 (fr) | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine | |
FR2912058A1 (fr) | Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles | |
FR2711527A1 (fr) | Utilisation de l'acriflavine comme agent anti HIV. | |
FR2527077A1 (fr) | Nouveau medicament a base d'un anti-depresseur et d'un alcaloide ergopeptidique | |
FR2585573A1 (fr) | Medicament pour prevenir l'abus d'alcool | |
FR2740343A1 (fr) | Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17P | Request for examination filed |
Effective date: 20011113 |
|
17Q | First examination report despatched |
Effective date: 20031024 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040308 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1041822 Country of ref document: HK |